Bicycle Therapeutics plc (ADR)
General ticker "BCYC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $462.1M (TTM average)
Bicycle Therapeutics plc (ADR) does not follow the US Stock Market performance with the rate: -20.4%.
Estimated limits based on current volatility of 2.1%: low 4.08$, high 4.26$
Factors to consider:
- Total employees count: 288 (-5.6%) as of 2025
- Top business risk factors: Operating losses, Market competition, Regulatory and compliance, Market acceptance, Reimbursement risks
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.60$, 11.37$]
- 2026-12-31 to 2027-12-31 estimated range: [4.63$, 11.33$]
Financial Metrics affecting the BCYC estimates:
- Positive: with PPE of -2.2 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.49 > -0.60
- Positive: Interest expense per share per price, % of 0.04 <= 0.74
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 85.00 > 64.23
Short-term BCYC quotes
Long-term BCYC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $26.98MM | $35.27MM | $72.59MM |
| Operating Expenses | $216.92MM | $245.15MM | $319.65MM |
| Operating Income | $-189.95MM | $-209.87MM | $-247.06MM |
| Non-Operating Income | $10.74MM | $36.08MM | $28.26MM |
| Interest Expense | $3.26MM | $1.73MM | $0.21MM |
| R&D Expense | $156.50MM | $172.97MM | $240.28MM |
| Income(Loss) | $-179.21MM | $-173.80MM | $-218.81MM |
| Taxes | $1.46MM | $-4.76MM | $0.15MM |
| Net Income(Loss)* | $-180.66MM | $-169.03MM | $-218.96MM |
| Stockholders Equity | $370.93MM | $793.06MM | $609.98MM |
| Assets | $595.34MM | $956.87MM | $717.60MM |
| Operating Cash Flow | $-60.63MM | $-164.72MM | $-249.68MM |
| Capital expenditure | $2.93MM | $1.24MM | $2.36MM |
| Investing Cash Flow | $-2.93MM | $-1.24MM | $-2.35MM |
| Financing Cash Flow | $250.03MM | $519.75MM | $-0.13MM |
| Earnings Per Share** | $-5.08 | $-2.90 | $-3.16 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.